Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GKOS 
Glaukos Corp (GKOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GKOS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 27.28% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.77B USD | Price to earnings Ratio - | 1Y Target Price 168.54 |
Price to earnings Ratio - | 1Y Target Price 168.54 | ||
Volume (30-day avg) 1150723 | Beta 1 | 52 Weeks Range 89.94 - 163.71 | Updated Date 04/1/2025 |
52 Weeks Range 89.94 - 163.71 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -38.17% | Operating Margin (TTM) -27.17% |
Management Effectiveness
Return on Assets (TTM) -7.06% | Return on Equity (TTM) -23.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5351846130 | Price to Sales(TTM) 15.05 |
Enterprise Value 5351846130 | Price to Sales(TTM) 15.05 | ||
Enterprise Value to Revenue 13.96 | Enterprise Value to EBITDA -57.89 | Shares Outstanding 56567400 | Shares Floating 54688287 |
Shares Outstanding 56567400 | Shares Floating 54688287 | ||
Percent Insiders 3.32 | Percent Institutions 102.34 |
Analyst Ratings
Rating 4.21 | Target Price 155.25 | Buy 3 | Strong Buy 8 |
Buy 3 | Strong Buy 8 | ||
Hold 2 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Glaukos Corp
Company Overview
History and Background
Glaukos Corp. was founded in 1998 and is focused on developing novel therapies for glaucoma. It pioneered iStent, the first FDA-approved micro-invasive glaucoma surgery (MIGS) device.
Core Business Areas
- Glaucoma: Develops and commercializes micro-invasive glaucoma surgery (MIGS) devices and sustained pharmaceutical therapies to lower intraocular pressure in patients with glaucoma.
- Cornea: Develops and commercializes bio-activated, implantable corneal inlays designed to treat presbyopia.
Leadership and Structure
The company is led by CEO Thomas Burns. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- iStent inject W: A micro-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with open-angle glaucoma. It is the next-generation iStent device and boasts improved features such as greater efficacy. Competing products include those from Ivantis (Hydrus Microstent) and Alcon (CyPass Micro-Stent - although Alcon took the stent off the market).
- iPrime: A device used to prime viscodelivery instruments to enhance intraoperative visualisation and allow for less IOP spike post-op. Competitors include New World Medical and Bausch and Lomb.
Market Dynamics
Industry Overview
The glaucoma and presbyopia treatment market is growing due to an aging population and increasing prevalence of these conditions. Technological advancements are driving the development of less invasive surgical and pharmaceutical options.
Positioning
Glaukos is a leader in the MIGS space, holding a significant market share with its iStent technology. The company is focused on expanding its product portfolio and market reach.
Total Addressable Market (TAM)
The total addressable market for glaucoma and presbyopia treatments is estimated to be billions of dollars annually. Glaukos is positioned to capture a significant portion of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- First-mover advantage in MIGS
- Established brand recognition
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Dependence on iStent sales
- Limited product diversification
- Regulatory risks associated with medical devices
- Reliance on reimbursement approvals
Opportunities
- Expanding into new geographic markets
- Developing new MIGS devices and sustained pharmaceutical therapies
- Acquiring complementary technologies and companies
- Addressing unmet needs in glaucoma and presbyopia treatment
Threats
- Increasing competition from established and emerging players
- Pricing pressures from healthcare providers and insurers
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- ALC
- ABBV
- NVAX
Competitive Landscape
Glaukos has a strong position in the MIGS market, but faces increasing competition from larger pharmaceutical and medical device companies. The company's innovative technology and focus on glaucoma treatment provide a competitive advantage.
Major Acquisitions
DuraMedix
- Year: 2023
- Acquisition Price (USD millions): 20
- Strategic Rationale: Acquisition to develop sustained pharmaceutical therapies
Growth Trajectory and Initiatives
Historical Growth: Glaukos has experienced significant growth in revenue due to the adoption of its iStent technology. Growth slowed as of 2023 due to supply chain issues and competition.
Future Projections: Future growth depends on the successful commercialization of new products and expansion into new markets. Analyst expectations vary based on these factors.
Recent Initiatives: Recent initiatives include the development of new MIGS devices, expansion into the pharmaceutical space with sustained-release drug delivery systems, and strategic acquisitions.
Summary
Glaukos is a pioneering company in micro-invasive glaucoma surgery with its iStent technology, holding a significant market share. While its dependence on iStent sales and potential regulatory risks represent challenges, expansion into new markets and development of innovative therapies offer growth opportunities. Competition from larger players and pricing pressures could impact the company's performance. Strategic acquisitions and a focus on innovation are key to Glaukos maintaining its leadership position in the glaucoma treatment market.
Similar Companies
- ALC
- ABBV
- NVAX
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Glaukos Corp
Exchange NYSE | Headquaters Aliso Viejo, CA, United States | ||
IPO Launch date 2015-06-25 | Chairman & CEO Mr. Thomas William Burns | ||
Sector Healthcare | Industry Medical Devices | Full time employees 995 | Website https://www.glaukos.com |
Full time employees 995 | Website https://www.glaukos.com | ||
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.